Back to Results

Biovaxys Technology Corp (BVAXF)

BioVaxys Technology Corp. is a clinical-stage biotechnology company listed on OTC Markets as common stock. The company focuses on viral and oncology vaccine platforms and immuno-diagnostics, with programs built around its DPX immune educating technology and HapTenix neoantigen tumor cell construct platform. Its development pipeline includes Maveropepimut-S (MVP-S), which has completed a phase IIb trial in advanced relapsed-refractory diffuse large B-cell lymphoma and platinum-resistant ovarian cancer, as well as MVP-S combined with Keytruda in a phase IIb study across several cancer subpopulations. Additional programs include BVX-0918 for ovarian cancer, DPX SurMAGE, and vaccine candidates such as DPX-RSV, DPX-Flu, DPX-Neo, DPX-E7, and DPX-rPA. The company is also pursuing collaborations for food allergy and companion animal vaccine applications. BioVaxys is headquartered in Etobicoke, Canada.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-BVAX.F
$0.047
-52.3% Downside
Expensive
Not available
Not available
Weak
0.0%
September 25, 2026
2.194 M
2.321 M
4.1%
89.7%
-118.4
49.8%
Valuation • Fair Value

Biovaxys Technology Corp (OTC-BVAX.F) Fair Value by Valuation Model

Review the available estimates for Biovaxys Technology Corp (OTC-BVAX.F), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.047

Estimated downside of 52.3% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.047

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Biovaxys Technology Corp (OTC-BVAX.F) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Biovaxys Technology Corp (OTC-BVAX.F)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Biovaxys Technology Corp (OTC-BVAX.F) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Biovaxys Technology Corp (OTC-BVAX.F)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

1

Weak quality score that deserves closer review.

Altman Z-Score

-118.4

Lower score that deserves closer risk review.

FCF / Net Income

49.8%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Biovaxys Technology Corp (OTC-BVAX.F). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Biovaxys Technology Corp (OTC-BVAX.F)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

September 25, 2026

Days to Earnings

3

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Biovaxys Technology Corp (OTC-BVAX.F), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for Biovaxys Technology Corp (OTC-BVAX.F) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for Biovaxys Technology Corp (OTC-BVAX.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Biovaxys Technology Corp (OTC-BVAX.F) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Biovaxys Technology Corp (OTC-BVAX.F) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Biovaxys Technology Corp (OTC-BVAX.F) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Biovaxys Technology Corp (OTC-BVAX.F) Stock FAQ

Data-supported answers about Biovaxys Technology Corp (OTC-BVAX.F), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.047
Estimated downside 52.3%
Valuation Rating
Overvalued
Estimated downside of 52.3%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Biovaxys Technology Corp (OTC-BVAX.F) is $0.047. This implies an estimated downside of 52.3% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 52.3% versus the current market price.

The current financial health read for Biovaxys Technology Corp (OTC-BVAX.F) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Biovaxys Technology Corp (OTC-BVAX.F) is September 25, 2026.

The latest available data indicates no current dividend yield for Biovaxys Technology Corp (OTC-BVAX.F).

The current market capitalization listed for Biovaxys Technology Corp is 2.194 M.

The current enterprise value listed for Biovaxys Technology Corp is 2.321 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Biovaxys Technology Corp is OTC-BVAX.F, and the stock is listed on OTC Markets.

Biovaxys Technology Corp (OTC-BVAX.F) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Biovaxys Technology Corp is 4.1%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Biovaxys Technology Corp is 89.7%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B